根据名称进行药物检索

Aceon 与 Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide

Aceon 与 Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide互相作用以及同时服用的可能性。

检测结果:

Aceon <> Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide

现实性: 08.09.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用普利与奥美可能会增加风险的副作用，例如低血压、肾功能障碍，这种情况称为高血钾(高血钾)。在严重的情况下，高血钾可能导致肾衰竭、肌肉麻痹、非正规心脏的节奏，和心脏骤停。你可以更容易患高血钾同时服用这些药物，如果你是老年人、脱水，或有肾脏病、糖尿病或高级心脏衰竭。定期或长期使用的非甾体抗炎药物，如布洛芬或生(止痛药)也可能增加你的风险。重要的是你保持足够的流体摄入量在处理与这些药物。谈谈你的医生如果你有任何疑问或关切的问题。你的医生可能已经知道的风险，但是已确定这是最好的治疗并采取适当的预防措施和监控你的密切对任何潜在并发症。此外，向你的医生询问如果这是你必须限制消费的钾丰富的食品，如西红柿、葡萄干图、马铃薯、青豆、香蕉、大蕉、番木瓜、梨、甜瓜、芒果、钾含盐的替代品。你应该寻求医疗照顾，如果你遇到恶心、呕吐、无力、混乱、麻刺的手和脚，感觉头重脚轻的腿,一个脉搏微弱，或者减缓或心跳不规则，因为可以将这些症状的高血钾. 重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：共同给予一个王牌抑制剂的组合有一个血管紧张素II受体拮抗剂可能会增加风险的高血钾，低血压、晕厥和肾功能障碍，由于加或协同作用于肾素-血管紧张素的系统。

管理：双重封锁的肾素血管紧张素醛固酮系统通过加入一个王牌抑制剂一个血管紧张素II受体拮抗剂不是建议，尤其是在患有糖尿肾病。大多数患者接受的组合没有获得任何额外的好处相比单一疗法。然而，如果结合被认为是必要的医疗、血电解质、血压、肾功能应密切监测。例行监测的电解质和肾功能可能表示在老年人或患者日益恶化的心脏故障或风险，对于脱水。补充钾通常应该避免，除非它被密切监视，并且患者应建议寻求医疗注意，如果他们的经验的迹象和症状的高血钾例如虚弱，无精打采，混乱，刺痛的肢体和心律不齐。

来源

"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.
"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim, Ridgefield, CT.
Rossing K, Jacobsen P, Pietraszek L, Parving HH "Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial." Diabetes Care 26 (2003): 2268-74
National Kidney Foundation "KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update." Am J Kidney Dis 60 (2012): 850-86
MHRA. Medicines and Healthcare Regulatory Agency "Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/" ([2014 June]):
ONTARGET Investigators, Yusuf S, Teo KK, et al "Telmisartan, ramipril, or both in patients at high risk for vascular events." N Engl J Med 358 (2008): 1547-59
Mann JF, Schmieder RE, McQueen M, et al. "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial." Lancet 372 (2008): 547-53
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D "Dual renin-angiotensin system blockade at optimal doses for proteinuria." Kidney Int 62 (2002): 1020-5
"Product Information. Atacand (candesartan)." Astra Pharmaceuticals, Wayne, PA.
EMA. European Medicines Agency "PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion. Available from: URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/R" ([2014 Apr 11]):
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both." N Engl J Med 349 (2003): 1893-1906
Jacobsen P, Andersen S, Jensen BR, Parving HH "Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy." J Am Soc Nephrol 14 (2003): 992-9
Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH "Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy." Kidney Int 63 (2003): 1874-80
Guthrie RM "Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary." Postgrad Med 121 (2009): 202-4
McMurray JJ, Ostergren J, Swedberg K, et al. "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial." Lancet 362 (2003): 767-71